Trials / Terminated
TerminatedNCT02616185
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PF-06755992 | PF-06755992 will be administered on Day 1 of Cycles 1 and 2. |
| BIOLOGICAL | PF-06755990 | PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle. |
| DEVICE | TDS-IM Electroporation Device | TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration |
| BIOLOGICAL | Tremelimumab | PF-06753388 will be administered every 28 days. |
| BIOLOGICAL | PF-06801591 | PF-06801591 will be administered every 28 days. |
| BIOLOGICAL | PF-06753512 | Combination of adenovirus (AdC68) + plasmid DNA (pDNA) + tremelimumab |
Timeline
- Start date
- 2015-12-30
- Primary completion
- 2021-02-23
- Completion
- 2021-02-23
- First posted
- 2015-11-26
- Last updated
- 2023-11-02
- Results posted
- 2023-11-02
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02616185. Inclusion in this directory is not an endorsement.